Rodman & Renshaw downgraded Viracta Therapeutics (VIRX) to Neutral from Buy with a price target of 25c, down from $3.50, after Viracta announced it has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas to maximize its cash runway while the board conducts a review of strategic alternatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIRX:
- Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
- Viracta Therapeutics announces exploration of strategic alternatives
- Viracta Therapeutics Highlights Strategic Focus and Financials
- Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year
- Viracta Therapeutics expects cash to fund operations into Q1 of 2025